# Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients

> **NCT03708549** · PHASE4 · UNKNOWN · sponsor: **Tianjin Anding Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Schizophrenia
- Metabolic Syndrome
- Berberine
- Metformin

## Interventions

- **DRUG:** Berberine
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03708549
- **Lead sponsor:** Tianjin Anding Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708549, "Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03708549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*